Simplified Access to Medicinal Cannabis in NSW
Perth, Mar 2, 2018 AEST (ABN Newswire) - MMJ PhytoTech Limited (
ASX:MMJ) ("MMJ") welcomes today's announcement by the NSW Government outlining plans to simplify access to medicinal cannabis for doctors and patients in NSW. A copy of that announcement is available at:
http://www.abnnewswire.net/lnk/I15N96IO
The streamlined approval process will see NSW Health partner with the Commonwealth to require a single clinical assessment by the Therapeutic Goods Administration. This key change will eliminate duplication from the current approval process and substantially shorten the time between application and approval for doctors in NSW to prescribe medicinal cannabis to their patients.
This is an important proposed change given that MMJ's largest investment, Harvest One Cannabis Inc. (CVE:HVST), currently supplies Satipharm CBD capsules to approved patients in Australia.
About MMJ Group Holdings Ltd
MMJ Group Holdings Ltd (ASX:MMJ) is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: https://www.mmjphytotech.com.au/investors/
| ||
|
